A 2 1/2 year-old infant appears to have been cured of HIV following aggressive treatment soon...

A 2 1/2 year-old infant appears to have been cured of HIV following aggressive treatment soon after birth with the drugs lamivudine and zidovudine, which are sold by a joint venture between GlaxoSmithKline (GSK), Pfizer (PFE), ViiV Healthcare and Abbott Laboratories' (ABT) Kaletra. The news could revolutionize the way babies with HIV are treated. "It's proof of principle that we can cure HIV infection if we can replicate this case," says Johns Hopkins' Deborah Persaud, the lead author of a report on the case.

From other sites
Comments (5)
  • RobertPowell
    , contributor
    Comments (11) | Send Message
    It will be a good day for GSK and PFE.
    4 Mar 2013, 07:02 AM Reply Like
  • jmodrkrk
    , contributor
    Comments (94) | Send Message
    wow, all investment notion aside, that's pretty incredible.
    4 Mar 2013, 07:16 AM Reply Like
  • LumiaMan
    , contributor
    Comments (323) | Send Message
    trust me, niether of those compnays want to cure it, only treatment, it would not be in best interst of corporate profits to cure it, although best for man kind. No money it cures
    4 Mar 2013, 09:04 AM Reply Like
  • MexCom
    , contributor
    Comments (3077) | Send Message
    The target treatment group is large but the population is in poorer countries. No block-buster here but it could lead to other treatments.
    4 Mar 2013, 09:57 AM Reply Like
  • oldfolks
    , contributor
    Comments (59) | Send Message
    your pessimism is showing. I choose to believe that given PFE's R&D costs (others also) that these companies are truly interested in cures. The folks that work for these drug companies couldn't possibly be in a conspiracy to do anything but.
    Anyway, I always have looked at the glass half full rather...
    4 Mar 2013, 01:03 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs